SGBCC 2023 – thank you!
We would like to express our sincere gratitude for your valuable contribution to the 18th St.Gallen International Breast Cancer Conference 2023. It brings us great pleasure to see so many delegates come together every two years to learn about the latest developments in the treatment of individuals with early breast cancer, and your presence and contribution played an integral part in making the conference a success.
As per tradition, the conference concluded with an update on the widely acknowledged „St.Gallen International Consensus on the Primary Treatment of Individuals with Early Breast Cancer,“ which will be published just a few months after the conference.
Once again, we would like to thank you for your participation and contribution to this important event, and we hope to see you again in 2025!
Save the date!
The next St. Gallen International Breast Cancer Conference will take place from 12 – 15 March 2025 in Vienna. We cordially invite you to mark this date in your agenda today. Don’t miss any news and sign up for our newsletter or join us on social media to stay informed. We look forward to welcoming you at SGBCC 2025!
Your SGBCC 2023 Organising Team
St.Gallen Oncology Conferences
Rorschacherstrasse 150, 9006 St.Gallen/Switzerland
sgbcc@oncoconferences.ch
www.sg-bcc.org
conference programme
Understanding breast cancer complexity to improve patients outcomes
scientific programme quick-links
> Wednesday, 15 March 2023
Opening Ceremony: Welcome, Awards and Award Lectures
Chairs: Michael Gnant (Austria), Beat Thürlimann (Switzerland), Walter Weber (Switzerland)
St.Gallen Breast Cancer Award 2023
Chairs: Beat Thürlimann (Switzerland), Walter Weber (Switzerland)
The St.Gallen Breast Cancer Award Lecture 2023:
The Saga of Theragnostic Biomarkers of Breast Cancer (Giuseppe Viale, Italy)
ESO Umberto Veronesi Memorial Award 2023
Chair: Alexandru Eniu (ESO)
The ESO Umberto Veronesi Memorial Award Lecture 2023:
A global approach to breast cancer management (Benjamin Anderson, WHO)
Short break
Best Poster Awards 2023
Chair: Beat Thürlimann (Switzerland)
Session 1: News in breast cancer care since SGBCC 2021
Chairs: Beat Thürlimann (Switzerland), Tanja Spanic (Slovenia)
- Surgery of patients with early breast cancer: Quo vadis? (Walter Weber, Switzerland)
- Access to evidence based radiation therapy for patients with early breast cancer (Philip Poortmans, Belgium)
- What’s new in systemic treatment of patients with early breast cancer (Roisin Connolly, Ireland)
- Translational research priorities for patients with early breast cancer (Fabrice André, France)
- Hot topics in survivorship, patient reported outcomes, and Quality of Life (Ann Partridge, USA)
Coffee break
SGBCC Academy
The St.Gallen-Vienna Breast Cancer Care Educationals for Professionals around the world.
Chair: Emiel Rutgers (Netherlands)
Co-Chair: Sara Brucker (Germany)
Discussants: Stefan Aebi (Switzerland), Meteb Al-Foheidi (KSA), Zefei Jiang (China), Toru Watanabe (Japan)
Interactive Session I: How to avoid unnecessary mastectomies – a global discussion
Chairs: Monica Morrow (USA), Walter Weber (Switzerland)
Panelists: Meteb Al-Foheidi (KSA), Denisse Bretel (Peru), Jana de Boniface (Sweden), Fatima Cardoso (Portugal), Heba Gamal (Egypt), Eun-Sook Lee (Korea), Lori Pierce (USA), Zhiming Shao (China), Tanja Spanic (Slovenia), Masakazu Toi (Japan)
Welcome Apéro at the Austria Center Vienna
> Thursday, 16 March 2023
Session 2: Genomics, Transcriptomics, ctDNA for disease monitoring and risk stratification
Chairs: Fabrice André (France), Meredith Regan (USA)
- ctDNA dynamics for early assessment of recurrence risk (Nicholas Turner, UK)
- Molecular imaging in breast cancer (Michel van Kruchten, Netherlands)
- Multi-omic machine learning prediction of treatment response (Carlos Caldas, UK)
- How to assess clinical utility and clinical validity of biomarkers in clinical trials? (Meredith Regan, USA)
Session 3: Immunology in early breast cancer
Chairs: Sherene Loi (Australia), Aleix Prat (Spain)
- Understanding the anti-cancer immune response: Innate and adaptive responses to breast cancer cells (Sherene Loi, Australia)
- Tumor microenvironment in early breast cancer (Carsten Denkert, Germany)
- Multiplexed analysis and spatial histology to predict response (Marleen Kok, Netherlands)
- The future of breast cancer immunotherapy (PD, PDL, vaccines) (Giuseppe Curigliano, Italy)
Lunch break
Special lecture I and panel discussion
Chair: Michael Gnant (Austria)
Panelists: David Cameron (UK), Heba Gamal (Egypt), Chiun-Sheng Huang (Taiwan)
Special lecture I
The future of innovation: Why are we conducting clinical trials in countries that are unlikely to be able to afford innovative drugs? (Sara Tolaney, USA)
Session 4: Hereditary Breast Cancer
Chairs: Lisa Carey (USA), Suzette Delaloge (France)
- Imaging, screening & surveillance for individuals with increased hereditary breast cancer risk (Suzette Delaloge, France)
- Local treatment in patients with high risk hereditary breast cancer (Maria Joao Cardoso, Portugal)
- Management of patients harboring medium penetrance genes (Christian Singer, Austria)
- Adjuvant systemic therapy for patients with germline BRCA1/2 mutations (Andrew Tutt, UK)
Session 5: The future treatment landscape in the adjuvant setting
Chairs: Sibylle Loibl (Germany), Martine Piccart (Belgium)
- Post-neoadjuvant options in triple negative disease: PARPi, capecitabine, checkpoint inhibitors (Javier Cortes, Spain)
- Risk assessment in ER positive disease: Who should receive CDK 4-6 inhibitors? (Angela De Michele, USA)
- What’s next? Antibody drug conjugates for breast cancer therapy (Cristina Saura, Spain)
- Integrating new oral SERDs in the adjuvant treatment (David Cameron, UK)
Coffee break
SGBCC Academy
The St.Gallen-Vienna Breast Cancer Care Educationals for Professionals around the world.
Chair: Fatima Cardoso (Portugal)
Co-Chair: Carlos Barrios (Brazil)
Discussants: Jonas Bergh (Sweden)
Debate I: Early breast cancer: do we need chemotherapy in low genomic/high clinical risk (ER+/HER2-)?
Chairs: Giuseppe Curigliano (Italy), Michael Gnant (Austria)
Debaters: Lisa Carey (USA), Nadia Harbeck (Germany)
Interactive Session II: Too big, too small? Too low, too high? Adjuvant choices when stage and biology do not align.
Chairs: Harold Burstein (USA), Prudence Francis (Australia)
Panelists: Charlotte Coles (UK), Eun-Sook Lee (Korea), Frederique Penault-Llorca (France), Martine Piccart (Belgium), Cristina Saura (Spain), Andrew Tutt (UK)
What to do in discordant scenarios? Small tumors with high biological risk? (Case studies)
> Friday, 17 March 2023
Session 6: Tailoring breast surgery and radiotherapy
Chairs: Jana de Boniface (Sweden), Lori Pierce (USA)
- Patient selection, dose and fractionation for external beam radiotherapy in patients with early breast cancer (Charlotte Coles, UK)
- Benefits and risks of oncoplastic breast-conserving surgery (Marie-Jeanne Vrancken Peeters, Netherlands)
- Breast surgery after neoadjuvant therapy (Andrea V. Barrio, USA)
- Breast surgery for local recurrence (Isabel Rubio, Spain)
Session 7: Controversies in the treatment of the axilla
Chairs: Philip Poortmans (Belgium), Zhiming Shao (China)
- Omission of surgical staging of the axilla (Oreste Gentilini, Italy)
- Axillary surgery in the adjuvant setting (Jana de Boniface, Sweden)
- Limited axillary surgery concepts to determine nodal pathologic complete response (Jörg Heil, Germany)
- De-escalation of axillary radiotherapy – the time has come! (Icro Meattini, Italy)
Lunch break
Best Poster Presentations
Chair: Beat Thürlimann (Switzerland)
Debate II: Axillary dissection versus axillary radiation for residual nodal disease after neoadjuvant systemic therapy
Chairs: Michal Gnant (Austria), Philip Poortmans (Belgium)
Debaters: Orit Kaidar-Person (Israel), Monica Morrow (USA)
Interactive Session III: Controversies and uncertainties in axillary management
Chairs: Walter Weber (Switzerland), Bahadir Gulluoglu (Turkey)
Panelists: Jana de Boniface (Sweden), Oreste Gentilini (Italy), Orit Kaidar-Person (Israel), Eun-Sook Lee (Korea), Monica Morrow (USA), Philip Poortmans (Belgium), Isabel Rubio (Spain), Marie-Jeanne Vrancken Peeters (Netherlands)
Short break
SGBCC Academy
The St.Gallen-Vienna Breast Cancer Care Educationals for Professionals around the world.
Chair: Elzbieta Senkus-Konefka (Poland)
Co-Chair: Gerd Fastner (Spain)
Discussant Chiun-Sheng Huang (Taiwan)
Session 8: Optimizing treatment in patients with HER2-positive breast cancer
Chairs: Hope S. Rugo (USA), Masakazu Toi (Japan)
- Assessing HER2 heterogeneity (Frederique Penault-Llorca, France)
- Current adjuvant and neoadjuvant approaches (Nadia Harbeck, Germany)
- Emerging new treatments in HER2 positive breast cancer (Martine Piccart, Belgium)
- ER positive vs ER negative: tackling diversity in HER2 positive breast cancer (Aleix Prat, Spain)
Session 9: Optimizing treatment in patients with triple negative breast cancer
Chairs: Lisa Carey (USA), Zefei Jiang (China)
- Optimal neoadjuvant and adjuvant therapy for patients with early triple negative breast cancer (Hope S. Rugo, USA)
- Optimal systemic therapy for residual disease in TNBC (Sibylle Loibl, Germany)
- Tackling triple negative histological subtypes in early breast cancer (Jorge Reis Filho, USA)
- Can we de-escalate immunotherapy and chemotherapy in TNBC? (Hervè Bonnefoi, France)
Debate III: If you achieve pCR after neoadjuvant, do you need adjuvant therapy?
Chairs: Giuseppe Curigliano (Italy), Sherene Loi (Australia),
Debaters: Sibylle Loibl (Germany), Steven Chia (Canada)
Short break
> Saturday, 18 March 2023
Session 10: Global Prespective on breast cancer treatment
Chairs: Carlos Barrios (Brazil), Binghe Xu (China)
- Breast cancer treatment and research from a global perspective (Benjamin Anderson, World Health Organization)
- Perspective from Asia (Binghe Xu, China)
- Perspective from Africa (Heba Gamal, Egypt)
- Perspective from Latin America (Denisse Bretel, Peru)
Session 11: Optimizing treatment in patients with HR positive breast cancer
Chairs: Stefan Aebi (Switzerland)
- What to do when there are many options? Integrating Olaparib in BRCA-associated ER positive tumors (Sara Brucker, Germany)
- Pre-menopausal: Who needs chemotherapy in the (neo)adjuvant setting? (Prudence Francis, Australia)
- Can we omit adjuvant endocrine therapy? (Fatima Cardoso, Portugal)
- Duration of endocrine therapy in early breast cancer (Jens Huober, Switzerland)
Short break
Debate IV: Surgery of the primary for stage IV disease
Chairs: William Gradishar (USA), Bahadir Gulluoglu (Turkey)
Presenting data: William Gradishar (USA)
Debaters: Rajendra Badwe (India), Florian Fitzal (Austria)
Lunch break
St.Gallen International Consensus Session I
St.Gallen International Consensus Session on the primary treatment of patients with breast cancer 2023
Seeking consensus on evidence and opinions
Moderator and Scientific Secretary: Harold Burstein (USA), Giuseppe Curigliano (Italy)
Short break
St.Gallen International Consensus Session II
St.Gallen International Consensus Session on the primary treatment of patients with breast cancer 2023
Seeking consensus on evidence and opinions
Moderator and Scientific Secretary: Harold Burstein (USA), Giuseppe Curigliano (Italy)
Farewell
St.Gallen International Consensus on the primary treatment of individuals with breast cancer
As per tradition, the SGBCC 2023 concluded with an update on the widely acknowledged „St. Gallen International Consensus on the Primary Treatment of Individuals with Early Breast Cancer.“
The list of the St.Gallen International Breast Cancer Consensus Panel 2023 can be found here.
Publication 2023
The St.Gallen Consensus and its related core issues will be published just a few months after the conference.
Publication 2021
Publication 2019:
Estimating the benefits of therapy for early-stage breast cancer: read the St.Gallen International Consensus Guidelines for the Primary therapy of early breast cancer 2019 here.
chairs
Meet our chairs:
Conference co-chairs
Univ. Prof. Dr. Michael Gnant, Medical University of Vienna / Austria
Prof. Dr. med. Beat Thürlimann, Breast Centre, Kantonsspital St.Gallen / Switzerland
Prof. Dr. Walter Weber, University Hospital Basel / Switzerland
Photo: SGBCC 2023 Opening Ceremony. From left to right: W. Weber, M. Gnant, B. Thürlimann
Scientific Programme-Planning Committee
Harold Burstein, Boston, USA
Giuseppe Curigliano, Milano/Italy
Michael Gnant, Vienna/Austria
Sibylle Loibl, Neu-Isenburg/Germany
Philip Poortmans, Antwerp/Belgium
Meredith Regan, Boston, USA
Hans-Jörg Senn (✝), St.Gallen/Switzerland
Beat Thürlimann, St.Gallen/Switzerland
Walter Weber, Basel/Switzerland
Eric Winer, New Haven, USA
Conference founder and honorary chair
Prof. Dr. med. Hans-Joerg Senn (* 28 March 1934, ✝ 13 January 2023), Foundation St.Gallen Oncology Conferences (SONK), St.Gallen / Switzerland
faculty members
Conflict of Interest Statements
All faculty members of the scientific programme have submitted a conflict of interest statement.
The summary of all statements is available here.
.
Aebi | Stephan | Switzerland | Luzerner Kantonsspital, Lucerne Cantonal Hospital |
Al-Foheidi | Meteb | KSA | Princess Noorah Oncology Center, National Guard Health Affairs |
Anderson | Benjamin | Switzerland | WHO |
André | Fabrice | France | Gustave Roussy |
Anikusko | Mikola | Ukraine | Kyiv City Clinical Oncology Center |
Badwe | Rajendra | India | Dr. E. Borges Marg, Parel, Tata Memorial Centre |
Barrio | Andrea V. | USA | Memorial Sloan Kettering Cancer Center |
Barrios | Carlos | Brazil | LACOG – Latin American Cooperative Oncology Group, Lacog – Oncoclínicas Group |
Bergh | Jonas | Sweden | Karolinska Institutet and University Hospital |
Bonnefoi | Hervé | France | Institut Bergonie Unicancer |
Bretel Morales | Denisse | Peru | GECOPERU – Medical Direction, Gecoperu |
Brucker | Sara | Germany | Tuebingen University Women’s Hospital |
Burstein | Harold J. | USA | Dana-Farber Cancer Institute |
Caldas | Carlos | UK | Cancer Research UK Cambridge Institute, University Of Cambrige |
Cameron | David | UK | Edinburgh Cancer Research, The University of Edinburgh, The University Of Edinburgh |
Cardoso | Fatima | Portugal | Champalimaud Cancer Center |
Cardoso | Maria Joao | Portugal | Champalimaud Foundation Breast Unit |
Carey | Lisa | USA | Lineberger Comprehensive Cancer Center |
Chia | Steven | Canada | BC Cancer, Vancouver Cancer Centre, BC Cancer – Vancouver Centre |
Coles | Charlotte | UK | University of Cambridge |
Connolly | Roisin | Ireland | Cancer Research at UCC and Cork University Hospital |
Cortes | Javier | Spain | INTERNATIONAL BREAST CANCER CENTER, IBCC |
Curigliano | Giuseppe | Italy | Istituto Europeo di Oncologia, IRCCS |
de Boniface | Jana | Sweden | Capio St. Göran’s Hospital, Capio St. Göran’s Hospital And Karolinska Institutet |
Delaloge | Suzette | France | Gustave Roussy |
DeMichele | Angela | USA | University of Pennsylvania |
Denkert | Carsten | Germany | Universitätsklinikum Griessen und Marburg, Philipps-University Marburg |
Fastner | Gerd | Austria | Department of Radiotherapy and Radio-Oncology, Paracelsus Medical University, University Hospital Salzburg |
Fitzal | Florian | Austria | Medical University of Vienna, Medical University Vienna |
Francis | Prudence | Australia | Peter MacCallum Cancer Centre, De, Peter MacCallum Cancer Centre |
Gamal | Heba | Egypt | National Cancer Institute, Cairo University |
Gentilini | Oreste | Italy | S.Raffaele University and Research Hospital, San Raffaele University and Research Hospital |
Gnant | Michael | Austria | Medical University Of Vienna – ABCSG |
Gradishar | William | USA / NCCN | Northwestern University Feinberg School of Medicine, Nccn/northwestern University |
Gulluoglu | Bahadir | Turkey | Marmara Universiy of Medicine, Marmara University School Of Medicine |
Harbeck | Nadia | Germany | Head of Breast Center, Oncological Therapy and Breast Clinical Trials Unit, University of Munich |
Heil | Jörg | Germany | Breast Unit Heidelberg |
Huang | Chiun-Sheng Huang | Taiwan | National Taiwan University Hospital |
Huober | Jens | Switzerland | Cantonal Hospital St.Gallen, Kantonsspital St.Gallen, Brustzentrum |
Jiang | Zefei | China | Fifth Medical Center of Chinese PLA General Hospital Beijing |
Kaidar-Person | Orit | Israel | Sheba Tel Hashomer, Oncology Institute, Sheba Medical Center |
Kok | Marleen | Netherlands | netherlands cancer institute, Netherlands Cancer Institute |
Lee | Eun-Sook | Korea | National Cancer Center |
Loi | Sherene | Australia | Peter MacCallum Cancer Centre, Peter MacCallum Cancer Centre |
Loibl | Sibylle | Germany | GBG Forschungs GmbH, Gbg Forschungs Gmbh |
Martin | Miguel | Spain | HOSPITAL GREGORIO MARAÑON |
Meattini | Icro | Italy | University of Florence, University Of Florence |
Morrow | Monica | USA | Memorial Sloan Kettering Cancer Center |
Partridge | Ann | USA | Dana Farber Cancer Institut |
Penault-Llorca | Frederique | France | Centre Jean Perrin, centre Jean Perrin UNICANCER |
Piccart | Martine | Belgium | Institut Jules Bordet, Institut Jules Bordet |
Pierce | Lori | USA | University of Michigan/, University Of Michigan |
Poortmans | Philip | Belgium | Iridium Netwerk & University Of Antwerp |
Prat | Aleix | Spain | August Pi i Sunyer Biomedical Research Institute |
Regan | Meredith | USA | Dana-Farber Cancer Institute,, Dana-farber Cancer Institute |
Reis-Filho | Jorge | USA | Memorial Sloan Kettering Cancer Center,, Memorial Sloan Kettering Cancer Center |
Rubio | Isabel | Spain | Clinica Universidad de Navarra, Clinica Universidad De Navarra |
Rugo | Hope | USA | niversity of California Comprehensive Cancer Center, Department of Medicine, Ucsf Helen Diller Family Comprehensive Cancer Center |
Rutgers | Emiel | Netherlands | Netherlands Cancer Institute/Dept. of Surgery |
Saura | Cristina | Spain | Vall d’Hebron University Hospital/ Vall D’Hebron Institute of Oncology (VHIO), Vall D’hebrón University Hospital |
Senkus | Elzbieta | Poland | Department of Oncology and Radiotherapy, Medical University of Gdańsk, Department of Oncology and Radiotherapy, Medical University of Gdańsk |
Shao | Zhiming | China | Fudan University Cancer Hospital/Department of Breast Surgery |
Singer | Christian | Austria | Medical University of Vienna, Medical University/Center for Breast Health |
Spanic | Tanja | Slovenia | Europa Donna |
Thuerlimann | Beat | Switzerland | Swiss Breast Care Zürich |
Toi | Masakazu | Japan | Kyoto University Hospital |
Tolaney | Sara | USA | Harvard Medcial School / Dana-Farber Cancer Institute, Dana-Farber Cancer Institute |
Turner | Nicholas | UK | Royal Marsden Hospital, Icr |
Tutt | Andrew | UK | The Institute of Cancer Research / Breast Cancer Research |
van Kruchten | Michel | Netherlands | University Medical Center of Groningen |
Viale | Giuseppe | Italy | European Institute of Oncology Milan |
Vrancken Peeters | Marie-Jeanne | Netherlands | netherlands cancer institute – antoni van leeuwenhoek, Netherlands Cancer Institute – Antoni Van Leeuwenhoek |
Watanabe | Toru | Japan | Hamamatsu Oncology Center |
Weber | Walter | Switzerland | University Hospital Basel |
Wildiers | Hans | Belgium | University Hospitals Leuven |
Xu | Binghe | China | Cancer Hospital, Chinese Academy of Medical Sciences/ |
subject to changes
abstracts
We have received and reviewed all submitted abstracts over the course of the past couple of months and we could not be more delighted about all the contributions!
accepted abstract
The list of all accepted abstracts can be found here.
During the conference all accepted submissions can be viewed as e-posters in the e-poster area and via the congress app.
book of abstracts
All accepted abstracts have been published in an electronic supplement issue to the journal “The Breast” by Elsevier Publishers. Click here to access the journal.
best poster awards 2023
A renowned reviewing team honours the three best poster abstracts with the St.Gallen Oncology Conferences Best Poster Award 2023. The awards were presented at the SGBCC 2023 on Wednesday, 15 March 2023.
SGBCC Academy
The St.Gallen-Vienna Breast Cancer Care Educationals for Professionals around the world
The SGBCC 2023 was a great success, bringing together leading experts in the field of breast cancer from around the world to share the latest research, best practices, and insights. The conference featured a range of engaging sessions, including keynote lectures, panel discussions, and interactive workshops, covering a broad range of topics related to breast cancer.
One of the highlights of the conference was the SGBCC Academy, which offered a series of lectures on the most important topics in early breast cancer care, delivered by the panelists of the St. Gallen Consensus. Attendees had the opportunity to access these lectures via the virtual conference platform and participate in daily SGBCC Academy sessions, where they could ask follow-up questions and engage in further discussions on the most pressing issues in patient care.
Looking ahead, we are excited to continue providing exceptional educational opportunities to our attendees. We invite you to mark your calendars for the next St. Gallen International Breast Cancer Conference, which will take place in Vienna from 12 – 15 March 2025. Stay tuned for updates and announcements about the program and speakers, and we look forward to seeing you there.
award winners
St.Gallen International Breast Cancer Award Winner 2023
The Foundation Council of “St.Gallen Oncology Conferences“ (SONK) honors Professor Giuseppe Viale for his extraordinary contribution in research and practice development in the treatment of individuals with breast cancer with the “St.Gallen International Breast Cancer Award 2023“, which was presented during the SGBCC 2023 on 15 March 2023.
Prof. Giuseppe Viale
European Institute of Oncology IRCCS, Milan / Italy
St.Gallen Oncology Conferences (SONK) is privileged to count on Prof. Giuseppe Viale as an active contributor and supporter of the St.Gallen International Breast Cancer Conference and Consensus Guidelines. He is the first pathologist to receive this Award. He added his scientific and professional perspective to provide truly interdisciplinary discussions for the benefit of the best treatment of individuals with early breast cancer. With the St.Gallen Breast Cancer Award 2023, the Foundation St.Gallen Oncology Conferences (SONK) wishes to honour Giuseppe Viale for his extraordinary contributions to breast cancer science.
Find out more about Prof. Giuseppe Viale.
ESO Umberto Veronesi Memorial Award Winner 2023
The European School of Oncology (ESO) honors Professor Benjamin Anderson with the “ESO Umberto Veronesi Memorial Award 2023“, which was presented during the SGBCC 2023 on 15 March 2023.
Prof. Benjamin Anderson
World Health Organization (WHO), Geneva / Switzerland
Ben Anderson, faculty portrait at the Fred Hutchinson Cancer Research Center, May 24, 2019, in Seattle, Washington.
Find out more about Prof. Benjamin Anderson
Former St.Gallen International Breast Cancer Award Winners
2021: Prof. Philip Poortmans, Wilrijk-Antwerp/BE
2019: Prof. Monica Morrow, New York/USA
2017: Prof. Martine Piccart-Gebhart, Brussels/BE
2015: Prof. Alan Coates, Cennential Park/AUS
2013: Prof. Aron Goldhirsch, Lugano/CH + Milano/IT
2011: Prof. V. Craig Jordan, Washington, DC/USA
2009: Prof. Richard Gelber, Boston, MA/USA
2007: Prof. Michael Baum, London/UK
2005: Prof. Umberto Veronesi, Milano/IT
2003: Dr. Gianni Bonadonna, Milano/IT and Dr. Bernard Fisher, Pittsburg, PA/USA
Certificate of attendance / CME credit points
The conference counts for 20 CME credit points from the ACOE and UEMS and is also recognised by the international equivalents.
In order to obtain your certificate of attendance, SONK requires feedback on its educational and organisational activities. Following the conference, we kindly ask all SGBCC 2023 participants to complete an online evaluation which was sent to you by e-mail after the conference. The certificate of attendance will be sent to you after completion of the online evaluation.
webcasts
We are pleased to announce that the webcasts of the St. Gallen International Breast Cancer Conference 2023 will be exclusively available to participants for the next 6 months, providing you with the opportunity to review and revisit the sessions that matter most to you. After this period, the webcasts will be made publicly accessible for everyone to benefit from.
Click here to view the webcasts of the SGBCC 2023.
The password to access the webcasts have been sent to all participants by e-mail.
We hope that these recordings will help you further enhance your knowledge and understanding of the latest developments in the field of breast cancer. Thank you for being a part of SGBCC 2023!
Click on the links below to view the webcasts of the St.Gallen International Breast Cancer Conferences of the previous years:
satellite symposia programme
Wednesday, 15 March 2023 | |
11.30 – 12.30 (CET) | Exact Sciences |
Thursday, 16 March 2023 | |
08.00 – 08.45 (CET) | Industry sponsored symposium organized by Medscape Oncology Global |
11.30 – 12.30 (CET) | Novartis Oncology |
Friday, 17 March 2023 | |
11.30 – 12.30 (CET) | Daiichi Sankyo Europe GmbH |
17.45 – 18.45 (CET) | Astra Zeneca |
Wednesday, 15 March 2023 | 11:30-12:30
Improve patient care with genomic testing to tailor adjuvant systemic treatment in early HR+, HER2- breast cancer
- Welcome + opening remarks – Valentina Guarneri (Italy)
- Genomic testing – where do we stand in terms of clinical evidence? – Valentina Guarneri (Italy)
- Identifying patients for Oncotype DX® testing in my clinical practice – Christos Markopoulos (Greece)
- Patient’s awareness and understanding of genomic testing– Richard Simcock (UK)
- Panel discussion and Q+A
Thursday, 16 March 2023 | 08:00-08:45 CET
Industry session organized by Medscape Oncology Global
Supported by an independent educational grant from Lilly
Conceptualizing Guidelines to Manage Patients with Hormone Receptor–Positive, HER2-Negative Early Breast Cancer
- Welcome and Introductions – Sara Tolaney (United States)
- Understanding Hormone Receptor-Positive, HER2-Negative Early Breast Cancer Treatment Guidelines – Giuseppe Curigliano (Italy), Sara M. Tolaney (United States)
- What If: A Case Review Exploring Clinical Decision-Making and Patient Management – Giuseppe Curigliano (Italy), Sara M. Tolaney (United States)
- Managing Adjuvant Therapy – Giuseppe Curigliano (Italy), Sara M. Tolaney (United States)
- Q&A – Giuseppe Curigliano (Italy), Sara M. Tolaney (United States)
Thursday 16 March 11:30-12:30 CET
The Rise of CDK4/6 Inhibitors in HR+/HER2− Early Breast Cancer: Impact For Patients
Chair: Peter A. Fasching (Germany)
Faculty: Eva Ciruelos (Spain)
- Welcome and Introduction – Peter A. Fasching (Germany)
- Unmet need and CDK4/6 inhibitors in HR+/HER2− early breast cancer – Eva Ciruelos (Spain)
- QOL and treatment adherence in the adjuvant setting – Peter A. Fasching (Germany)
- Closing and Key Takeaways – Peter A. Fasching (Germany)
- Live Q&A – All
Friday, 17 March 2023, 11:30-12:30 CET
Advances in HER2-expressing breast cancer treatment with antibody-drug conjugates (ADCs): From metastatic to early disease
Chair: Giuseppe Curigliano (Italy)
- Welcome and introduction – Giuseppe Curigliano (Italy)
- How next-generation ADCs impact outcomes in HER2-expressing metastatic breast cancer – Barbara Pistilli (France)
- Translating clinical experience with ADCs from HER2-positive metastatic breast cancer into the early disease setting – Javier Cortés (Spain)
- Expanding the use of ADCs in HER2-low early breast cancer: What are the key considerations? – Nadia Harbeck (Germany)
- Panel discussion – All faculty
- Wrap up and close – Giuseppe Curigliano (Italy)
Friday, 17th March 2023; 17:45–18:45 CET
Solving the puzzle: Tailoring treatment options in early breast cancer
- Welcome and introductions – Nadia Harbeck (Germany)
- Building on the biology: What has changed in the understanding of early breast cancer? – Nadia Harbeck (Germany)
- Sequencing in the spotlight: Making sense of new treatment options – Andrew Tutt
- Completing the picture: Multidisciplinary insights for the treatment of patients with eBC – Peter Dubsky, Carlos Barrios
- Panel discussion – All faculty
- Meeting close – Nadia Harbeck (Germany)
contact
St. Gallen Oncology Conferences (SONK)
Rorschacherstrasse 150
9006 St.Gallen / Switzerland
+41 71 243 09 90
sgbcc@oncoconferences.ch